- Reuters•11 days ago
India's small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries. Cut-price generics sold by India's small- and medium-sized drugmakers have been critical in bringing down prices there. A more protectionist stance by President Donald Trump, with the prospect of import tariffs and the U.S. boosting local drug manufacturing, mean the operating environment for smaller generic players will get worse, executives at Indian companies said.
- Bloomberg•13 days ago
Now they just have to survive Dr. Trump's trade prescriptions.
- Reuters•14 days ago
India's largest drugmaker Sun Pharmaceutical Industries said U.S. regulators plan to lift a ban on its Mohali plant in northern India, paving the way for a resumption of exports to the company's biggest market after four years. The move would come as a boost to Sun, whose U.S. growth has been hit over the past year as five of its plants face supply restrictions due to regulatory issues. Sun said on Tuesday the U.S. Food and Drug Administration (FDA) had informed it about the agency's plans to lift the ban on Mohali.
SUNPHARMA.NS: Summary for SUN PHARMACEUTICAL INR1(DEMAT) - Yahoo Finance
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
NSE - NSE Real Time Price. Currency in INR
Add to watchlist
|Day's range||693.70 - 702.55|
|52-week range||571.90 - 854.95|
|PE ratio (TTM)||22.91|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|